Matches in SemOpenAlex for { <https://semopenalex.org/work/W2272627972> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2272627972 endingPage "14620" @default.
- W2272627972 startingPage "14620" @default.
- W2272627972 abstract "14620 Background: Low-dose chemotherapy without scheduled breaks (metronomic chemotherapy) is thought to be anti-angiogenic. Inhibitors of the VEGF and the PDGF signaling pathways may augment this effect. We initiated a prospective, phase I pharmacokinetic (PK) and biomarker study to assess the safety of a rationally designed combination anti-angiogenesis strategy consisting of metronomic CTX, BV (anti-VEGF antibody), and IM (PDGF-receptor inhibitor). Methods: Cycle length was 28 days. Doses: BV 5 mg/kg IV q 14 d, CTX 25–50 mg PO QD, IM 400–800 mg PO QD. DLT was defined as any treatment (tx)-related grade 4 hematologic or grade 3/4 non-hematologic event during cycle 1. Quantification of circulating tumor cells (CTC), endothelial cells (CEC, aEC) and endothelial progenitor cells (EPC) was performed. Parameters measured by CT perfusion were assessed. Results: 13 pts with metastatic colorectal cancer have been enrolled: M/ F= 7/6; ECOG PS 0/1= 8/5; median age=56 (range 33–68). All pts had received prior BV and had disease refractory to standard chemotherapy. Pts have received tx for a median of 56 days (range 28–252 days); 1 cycle (3 pts), 2 cycles (7 pts) and 7+ cycles (2 pts). Dose level 0 (DL 0) was expanded to 6 pts after 1/3 initial pts was removed from the study for a Gr 2 gastrointestinal fistula (after cycle 1). DL+1 and DL+2 had no DLT’s. 1 pt has been enrolled on DL+3. The MTD has not been reached. Tx has been well tolerated; there have been no tx-related Gr 3/4 toxicites. The most common tx-related AE’s have been Gr 1/2 nausea, vomiting, and rash. Two pts (DL 0, DL+1) demonstrated SD lasting > 6 months; 1 pt had a 19% decrease in target lesions by RECIST. Conclusions: The combination of metronomic CTX, IM, and BV can be safely administered. Class related side effects have been seen. Preliminary clinical activity has been observed in a heavily-pretreated patient population. Enrollment to this study continues, with CTX and IM PK to be performed at the MTD. Updated clinical and biomarker data will be presented. Dose Levels DL CTX (D1- 28) IM (D1–28) BV (D1,15) 0 25 mg PO QD 400 mg PO QD 5 mg/kg IV +1 50 mg PO QD 400 mg PO QD 5 mg/kg IV +2 50 mg PO QD 300 mg PO BID 5 mg/kg IV +3 50 mg PO QD 400 mg PO BID 5 mg/kg IV Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech, Genentech™ BioOncology, Johnson & Johnson, sanofi-aventis Genentech™ BioOncology, Johnson & Johnson Genentech™ BioOncology, Novartis" @default.
- W2272627972 created "2016-06-24" @default.
- W2272627972 creator A5007537368 @default.
- W2272627972 creator A5033960518 @default.
- W2272627972 creator A5036064622 @default.
- W2272627972 creator A5037875642 @default.
- W2272627972 creator A5040650575 @default.
- W2272627972 creator A5042114605 @default.
- W2272627972 creator A5052347152 @default.
- W2272627972 creator A5070411005 @default.
- W2272627972 creator A5072641295 @default.
- W2272627972 creator A5077164875 @default.
- W2272627972 date "2008-05-20" @default.
- W2272627972 modified "2023-10-14" @default.
- W2272627972 title "Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors" @default.
- W2272627972 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.14620" @default.
- W2272627972 hasPublicationYear "2008" @default.
- W2272627972 type Work @default.
- W2272627972 sameAs 2272627972 @default.
- W2272627972 citedByCount "1" @default.
- W2272627972 crossrefType "journal-article" @default.
- W2272627972 hasAuthorship W2272627972A5007537368 @default.
- W2272627972 hasAuthorship W2272627972A5033960518 @default.
- W2272627972 hasAuthorship W2272627972A5036064622 @default.
- W2272627972 hasAuthorship W2272627972A5037875642 @default.
- W2272627972 hasAuthorship W2272627972A5040650575 @default.
- W2272627972 hasAuthorship W2272627972A5042114605 @default.
- W2272627972 hasAuthorship W2272627972A5052347152 @default.
- W2272627972 hasAuthorship W2272627972A5070411005 @default.
- W2272627972 hasAuthorship W2272627972A5072641295 @default.
- W2272627972 hasAuthorship W2272627972A5077164875 @default.
- W2272627972 hasConcept C112705442 @default.
- W2272627972 hasConcept C126322002 @default.
- W2272627972 hasConcept C126894567 @default.
- W2272627972 hasConcept C143998085 @default.
- W2272627972 hasConcept C2776694085 @default.
- W2272627972 hasConcept C2776755627 @default.
- W2272627972 hasConcept C2777802072 @default.
- W2272627972 hasConcept C2778822529 @default.
- W2272627972 hasConcept C2780394083 @default.
- W2272627972 hasConcept C31760486 @default.
- W2272627972 hasConcept C71924100 @default.
- W2272627972 hasConcept C90924648 @default.
- W2272627972 hasConceptScore W2272627972C112705442 @default.
- W2272627972 hasConceptScore W2272627972C126322002 @default.
- W2272627972 hasConceptScore W2272627972C126894567 @default.
- W2272627972 hasConceptScore W2272627972C143998085 @default.
- W2272627972 hasConceptScore W2272627972C2776694085 @default.
- W2272627972 hasConceptScore W2272627972C2776755627 @default.
- W2272627972 hasConceptScore W2272627972C2777802072 @default.
- W2272627972 hasConceptScore W2272627972C2778822529 @default.
- W2272627972 hasConceptScore W2272627972C2780394083 @default.
- W2272627972 hasConceptScore W2272627972C31760486 @default.
- W2272627972 hasConceptScore W2272627972C71924100 @default.
- W2272627972 hasConceptScore W2272627972C90924648 @default.
- W2272627972 hasIssue "15_suppl" @default.
- W2272627972 hasLocation W22726279721 @default.
- W2272627972 hasOpenAccess W2272627972 @default.
- W2272627972 hasPrimaryLocation W22726279721 @default.
- W2272627972 hasRelatedWork W1989798994 @default.
- W2272627972 hasRelatedWork W1996033399 @default.
- W2272627972 hasRelatedWork W1998188518 @default.
- W2272627972 hasRelatedWork W2095704084 @default.
- W2272627972 hasRelatedWork W2417717847 @default.
- W2272627972 hasRelatedWork W2543100265 @default.
- W2272627972 hasRelatedWork W2564597380 @default.
- W2272627972 hasRelatedWork W2982238418 @default.
- W2272627972 hasRelatedWork W4221044984 @default.
- W2272627972 hasRelatedWork W4231596293 @default.
- W2272627972 hasVolume "26" @default.
- W2272627972 isParatext "false" @default.
- W2272627972 isRetracted "false" @default.
- W2272627972 magId "2272627972" @default.
- W2272627972 workType "article" @default.